CTOs on the Move

NightstaRx

www.nightstarx.com

 
Nightstar is a private biopharmaceutical company focused on the development of therapies for retinal dystrophies. The Company’s lead programme is a retinal gene therapy for choroideremia, a rare inherited cause of blindness that affects around 1 in 50,000 people. Gene therapy has the potential to be an effective treatment for choroideremia and a range of other retinal dystrophies. The Company’s lead investors are Syncona LLP and NEA Inc. Syncona is an evergreen investment company, taking an active role in identifying, supporting and developing technologies with the potential to impact significantly the healthcare market of the future. NEA is a global ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.nightstarx.com
  • 81 Hartwell Ave Suite 100
    Lexington, MA USA 02421
  • Phone: +44 7817 868300

Executives

Name Title Contact Details

Funding

NightstaRx raised $45M on 06/30/2017

Similar Companies

ViiV Healthcare

ViiV Healthcare is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Appello Pharmaceuticals

Appello Pharmaceuticals is a Nashville, TN based preclinical-stage company focused on advancing novel positive allosteric modulators of mGlu4 for the treatment of Parkinson`s disease.

Sanofi

Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients` needs. Sanofi has core strengths in diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Recor Medical

The RADIANCE-HTN Clinical study is a randomized, controlled study to evaluate the Paradise Renal Denervation System intended to treat high blood pressure. The study will be in up to 40 hospitals in 5 countries (US, France, Germany, The Netherlands, UK...